Aaron Pace, MD
Dermatology · Tacoma, WANPI 1760646129
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,852 of the $2,222 with a category attached, or 83.3%. 14 manufacturers reported payments, led by AbbVie at 25.2% of the total. 2025 is the largest year on record at $998, more than ten times the $40 reported in 2019.
Across 97 payments — averaging $22.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$559
- Pfizer$523
- Johnson & Johnson$466
- E.r. Squibb & Sons, L.L.C.$146
- Novartis$143
- Sun Pharmaceutical Industries Inc.$136
- plus $249 from 8 others
Across 56 payments — averaging $2969.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$125K
- Boehringer Ingelheim International GmbH$30K
- Regeneron$11K
What the payments were for
- Food & beverage$1,85283%
- Education$37017%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 33 | $559 |
| Pfizer | 24 | $523 |
| Johnson & Johnson | 13 | $466 |
| E.r. Squibb & Sons, L.L.C. | 7 | $146 |
| Novartis | 6 | $143 |
| Sun Pharmaceutical Industries Inc. | 2 | $136 |
| Sanofi | 2 | $66 |
| Incyte Corporation | 2 | $38 |
| Dermavant Sciences, Inc. | 2 | $37 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 2 | $27 |
| Arcutis Biotherapeutics, Inc. | 1 | $25 |
| UCB, Inc. | 1 | $22 |
| Lilly USA, LLC | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
How this compares
$2,222 in reported general payments places this provider in the 65th percentile of 323 dermatology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ketoconazole | 257 | $4,929 |
| Clobetasol Propionate | 77 | $4,549 |
| Metronidazole | 92 | $3,709 |
| Betamethasone Dipropionate | 36 | $2,352 |
| Triamcinolone Acetonide | 114 | $1,358 |
| Fluorouracil | 15 | $826 |
| Fluocinonide | 20 | $728 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 39 | $660 |
| Clindamycin Phosphate | 16 | $656 |
| Ciclopirox | 18 | $624 |
| Hydrocortisone | 49 | $485 |
| Doxycycline Monohydrate | 18 | $447 |
| Hydroxychloroquine Sulfate | 14 | $381 |
| Imiquimod | 16 | $334 |
| Cephalexin | 99 | $262 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Tacoma
- Nicole CasslerTacoma$12K
- Clive LiuBellevue$2.9M
- Vivian ShiSeattle$971K
- William WerschlerSpokane$948K
- Daniel LevyBonney Lake$541K
- Daniel SugaiBellevue$302K
- Ting-Lin YangBellingham$124K
- James CollyerSeattle$115K
- Cameron ChesnutSpokane$93K
- Alison YoungSeattle$53K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.